Abstract
Aims
This study was a real-world, retrospective evaluation of the clinical effectiveness
of switching to continuous subcutaneous insulin infusion (CSII) among managed care
enrollees with type 2 diabetes for whom multiple daily injections (MDI) had presumably
failed.
Methods
Administrative claims with integrated A1C values from a large and geographically diverse
health plan were analyzed.
Results
Statistically significant A1C reductions (from the baseline period to follow-up period,
mean follow-up 17 months) were achieved with CSII. Among subjects using a long-acting
and rapid-acting insulin regimen at baseline, A1C decreased to mean follow-up A1C
by 0.8% and to minimum follow-up A1C by 1.2% (p < 0.001). The proportion of subjects at target (A1C < 7%) increased significantly from baseline to follow-up (8.4–22.9% [using mean A1C]
and 32.8% [using minimum A1C]; both p < 0.001). The rate of severe hypoglycemic events was similar from baseline to follow-up.
Conclusions
CSII was associated with significant reductions in A1C without an increase in hypoglycemic
events in insulin-taking people with type 2 diabetes, including subjects previously
using a long-acting and rapid-acting insulin regimen.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Primary Care DiabetesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes.Diabetes Care. 2008; 31: S140-S145
- Clinical review: hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections.J. Clin. Endocrinol. Metab. 2009; 94: 729-740
- Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis.Exp. Clin. Endocrinol. Diabetes. 2009; 117: 220-222
- Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.Diabetologia. 2008; 51: 941-951
- A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes.Diabetes Care. 2005; 28: 1568-1573
- Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study.Diabetes Care. 2003; 26: 2598-2603
- Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients.Diabet. Med. 2005; 22: 1037-1046
- Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.Lancet. 2008; 371: 1753-1760
- Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure.Horm. Metab. Res. 2007; 39: 224-229
- Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.J. Am. Geriatr. Soc. 2007; 55: 182-188
- Long-term efficacy and safety of insulin detemir compared to neutral protamine gagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.Diabet. Med. 2008; 25: 442-449
- Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.Diabetes Care. 2005; 28: 254-259
- Long-term treatment combining continuous subcutaneous insulin infusion with oral hypoglycaemic agents is effective in type 2 diabetes.Diabet. Metab. 2007; 33: 253-260
- Standards of medical care in diabetes—2010.Diabetes Care. 2009; 33: S11-S61
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N. Engl. J. Med. 1993; 329: 977-986
- Epidemiology of severe hypoglycemia in the diabetes control and complications trial.Am. J. Med. 1991; 90: 450-459
Article info
Publication history
Published online: September 14, 2010
Accepted:
July 20,
2010
Received in revised form:
July 17,
2010
Received:
February 25,
2010
Identification
Copyright
© 2010 Primary Care Diabetes Europe. Published by Elsevier Inc. All rights reserved.
